Translational application of BCLXL gene therapy will also require evaluating the safety issues associated with long-term expression of this anti-apoptotic protein, including its possible effects on tumorigenesis [53, 54] and increased susceptibility to viral infections [55]. This evidence concerns the gene BCL2L1 and viral infectious disease.